139 related articles for article (PubMed ID: 30633776)
1. Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation.
Speich B; Schur N; Gryaznov D; von Niederhäusern B; Hemkens LG; Schandelmaier S; Amstutz A; Kasenda B; Pauli-Magnus C; Ojeda-Ruiz E; Tomonaga Y; McCord K; Nordmann A; von Elm E; Briel M; Schwenkglenks M;
PLoS One; 2019; 14(1):e0210669. PubMed ID: 30633776
[TBL] [Abstract][Full Text] [Related]
2. Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list.
Speich B; von Niederhäusern B; Blum CA; Keiser J; Schur N; Fürst T; Kasenda B; Christ-Crain M; Hemkens LG; Pauli-Magnus C; Schwenkglenks M; Briel M;
J Clin Epidemiol; 2018 Apr; 96():73-83. PubMed ID: 29292203
[TBL] [Abstract][Full Text] [Related]
3. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data.
Speich B; von Niederhäusern B; Schur N; Hemkens LG; Fürst T; Bhatnagar N; Alturki R; Agarwal A; Kasenda B; Pauli-Magnus C; Schwenkglenks M; Briel M;
J Clin Epidemiol; 2018 Apr; 96():1-11. PubMed ID: 29288136
[TBL] [Abstract][Full Text] [Related]
4. Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit Recommendations in Switzerland, CAnada and GErmany (ASPIRE-SCAGE).
Gryaznov D; von Niederhäusern B; Speich B; Kasenda B; Ojeda-Ruiz E; Blümle A; Schandelmaier S; Mertz D; Odutayo A; Tomonaga Y; Amstutz A; Pauli-Magnus C; Gloy V; Lohner S; Bischoff K; Wollmann K; Rehner L; Meerpohl JJ; Nordmann A; Klatte K; Ghosh N; Taji Heravi A; Wong J; Chow N; Hong P; McCord-De Iaco KA; Sricharoenchai S; Busse JW; Agarwal A; Saccilotto R; Schwenkglenks M; Moffa G; Hemkens L; Hopewell S; Von Elm E; Briel M
BMJ Open; 2022 May; 12(5):e053417. PubMed ID: 35613804
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects.
Gryaznov D; Odutayo A; von Niederhäusern B; Speich B; Kasenda B; Ojeda-Ruiz E; Blümle A; Schandelmaier S; Mertz D; Tomonaga Y; Amstutz A; Pauli-Magnus C; Gloy V; Bischoff K; Wollmann K; Rehner L; Lohner S; Meerpohl JJ; Nordmann A; Klatte K; Ghosh N; Heravi AT; Wong J; Chow N; Hong PJ; Cord KM; Sricharoenchai S; Busse JW; Agarwal A; Saccilotto R; Schwenkglenks M; Moffa G; Hemkens LG; Hopewell S; von Elm E; Briel M
Trials; 2020 Oct; 21(1):896. PubMed ID: 33115541
[TBL] [Abstract][Full Text] [Related]
6. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
[TBL] [Abstract][Full Text] [Related]
7. Analysis of time to regulatory and ethical approval of SATVI TB vaccine trials in South Africa.
Geldenhuys H; Veldsman A; Tameris M; Luabeya A; Hanekom W; Mahomed H; Hatherill M
S Afr Med J; 2012 Nov; 103(2):85-9. PubMed ID: 23374302
[TBL] [Abstract][Full Text] [Related]
8. Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study).
Kasenda B; von Elm EB; You J; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Meerpohl J; Stegert M; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla S; Mertz D; Akl EA; Bassler D; Busse JW; Ferreira-González I; Lamontagne F; Nordmann A; Rosenthal R; Schandelmaier S; Sun X; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Bucher HC; Guyatt GH; Briel M
BMC Med Res Methodol; 2012 Aug; 12():131. PubMed ID: 22928744
[TBL] [Abstract][Full Text] [Related]
9. Research ethics committees and post-approval activities: a qualitative study on the perspectives of European research ethics committee representatives.
Cox S; Solbakk JH; Bernabe RDLC
Curr Med Res Opin; 2022 Nov; 38(11):1897-1907. PubMed ID: 35993742
[TBL] [Abstract][Full Text] [Related]
10. Funding characteristics of randomised clinical trials supported by the Swiss National Science Foundation: a retrospective cohort study.
Amstutz A; Schandelmaier S; Frei R; Surina J; Agarwal A; Alturki R; von Niederhäusern B; von Elm E; Briel M; On Behalf Of The MAking Randomized Trials Affordable Marta Group
Swiss Med Wkly; 2018; 148():w14587. PubMed ID: 29376558
[TBL] [Abstract][Full Text] [Related]
11. Time to institutional review board approval with local versus central review in a multicenter pragmatic trial.
Neuman MD; Gaskins LJ; Ziolek T;
Clin Trials; 2018 Feb; 15(1):107-111. PubMed ID: 28982261
[TBL] [Abstract][Full Text] [Related]
12. Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management.
McLennan S; Griessbach A; Briel M;
JAMA Netw Open; 2021 Jun; 4(6):e2111847. PubMed ID: 34076698
[TBL] [Abstract][Full Text] [Related]
13. Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study.
Gloy V; McLennan S; Rinderknecht M; Ley B; Meier B; Driessen S; Gervasoni P; Hirschel B; Benkert P; Gilles I; von Elm E; Briel M
Swiss Med Wkly; 2020 Aug; 150():w20318. PubMed ID: 32799307
[TBL] [Abstract][Full Text] [Related]
14. Time required to initiate a clinical trial in Canada at the onset of the COVID-19 pandemic: an observational research-in-motion study.
Teo K; Fowler RA; Adhikari NKJ; Rishu A; Tsang JLY; Binnie A; Murthy S;
CMAJ Open; 2023; 11(4):E615-E620. PubMed ID: 37402556
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study.
Speich B; Odutayo A; Peckham N; Ooms A; Stokes JR; Saccilotto R; Gryaznov D; von Niederhäusern B; Copsey B; Altman DG; Briel M; Hopewell S
Trials; 2022 Jul; 23(1):601. PubMed ID: 35897110
[TBL] [Abstract][Full Text] [Related]
16. Identifying structures, processes, resources and needs of research ethics committees in Egypt.
Sleem H; El-Kamary SS; Silverman HJ
BMC Med Ethics; 2010 Jun; 11():12. PubMed ID: 20584332
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the ethical review process for non-pharmacological multicentre studies in Germany on the basis of a randomised surgical trial.
Seiler CM; Kellmeyer P; Kienle P; Büchler MW; Knaebel HP;
J Med Ethics; 2007 Feb; 33(2):113-8. PubMed ID: 17264200
[TBL] [Abstract][Full Text] [Related]
18. Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis.
Speich B; Gryaznov D; Busse JW; Gloy VL; Lohner S; Klatte K; Taji Heravi A; Ghosh N; Lee H; Mansouri A; Marian IR; Saccilotto R; Nury E; Kasenda B; Ojeda-Ruiz E; Schandelmaier S; Tomonaga Y; Amstutz A; Pauli-Magnus C; Bischoff K; Wollmann K; Rehner L; Meerpohl JJ; Nordmann A; Wong J; Chow N; Hong PJ; Mc Cord-De Iaco K; Sricharoenchai S; Agarwal A; Schwenkglenks M; Hemkens LG; von Elm E; Copsey B; Griessbach AN; Schönenberger C; Mertz D; Blümle A; von Niederhäusern B; Hopewell S; Odutayo A; Briel M
PLoS Med; 2022 Apr; 19(4):e1003980. PubMed ID: 35476675
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, characteristics, and publication of discontinued randomized trials.
Kasenda B; von Elm E; You J; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Meerpohl JJ; Stegert M; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla SM; Mertz D; Akl EA; Bassler D; Busse JW; Ferreira-González I; Lamontagne F; Nordmann A; Gloy V; Raatz H; Moja L; Rosenthal R; Ebrahim S; Schandelmaier S; Xin S; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Hemkens LG; Bucher HC; Guyatt GH; Briel M
JAMA; 2014 Mar; 311(10):1045-51. PubMed ID: 24618966
[TBL] [Abstract][Full Text] [Related]
20. The role of research ethics committees after the approval of clinical trial protocols in the EU and the USA: a descriptive content analysis of international and regional normative documents.
Cox S; Solbakk JH; Bernabe RDLC
Curr Med Res Opin; 2021 Jun; 37(6):1061-1069. PubMed ID: 33734933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
